EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Tag

protein

Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer

Basilea Pharmaceutica has started a study of a drug that inhibits the cancer-driving protein FGFR. It will be studied alone and with...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News
Your New Normal

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

1 day ago

Recent data showing positive results from a trial combining durvalumab (Imfinzi) with FLOT chemotherapy will be “practice changing,” said Gastric Cancer Foundation grantee Samuel Klempner of Massachusetts General Hospital. Via Targeted Oncology ... See MoreSee Less

Dr Klempner Highlights Practice-Changing Role of Durvalumab/FLOT in Gastric Cancer

www.targetedonc.com

Durvalumab enhances event-free survival in resectable gastric and gastroesophageal cancers, revolutionizing neoadjuvant therapy according to the MATTERHORN trial.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

4 days ago

Amgen ’s experimental gastric cancer drug bemarituzumab, which targets FGFR2b overexpression, improved overall survival when combined with chemotherapy in a phase 3 clinical trial. ... See MoreSee Less

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER| Amgen

www.amgen.com

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 week ago

In a comprehensive review, researchers at Chinese University of Hong Kong identified several risk factors for gastric cancer, including two stomach microbes, Streptococcus anginosus and Fusobacterium nucleatum. ... See MoreSee Less

New insights into the role of diet and microbiome in gastric cancer

www.news-medical.net

Gastric cancer (GC), once primarily seen in older adults, is on the rise among younger individuals in developed countries.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

Good news in gastric cancer: global prevalence has declined in the last six decades, possibly due to a 16% drop in H. pylori infections since 1980. Via MedPage Today ... See MoreSee Less

Gastric Cancer's Changing Trends in Incidence and Risk Factors

www.medpagetoday.com

Lower global prevalence of H. pylori infection may be the main driver of declining rates

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

What is life like after gastric surgery? Hans Rueffert, GCF’s “chef without a stomach” thinks of it as replacing a turbo diesel engine with an electric hybrid. If you try to put diesel fuel into it, you won’t get far. Check out his eating tips from the recent PALEMA Cancer Day in Sweden: ... See MoreSee Less

PALEMAcancerdagen 2025 - Hans Rueffert, en kock utan mage

youtu.be

En kock utan mage - Hans Rueffert, 20-årig magsäckscanceröverlevare (Engelska)

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

X